Spice’ Phenomenon 1
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Bath Salts and Synthetic Marijuana: an Emerging Threat by Rommie L
Continuing Education Course Bath Salts and Synthetic Marijuana: An Emerging Threat BY ROMMIE L. DUCKWORTH TRAINING THE FIRE SERVICE FOR 135 YEARS To earn continuing education credits, you must successfully complete the course examination. The cost for this CE exam is $25.00. For group rates, call (973) 251-5055. Bath Salts and Synthetic Marijuana: An Emerging Threat Educational Objectives On completion of this course, students will 1) Define the term “Designer Drug”. 3) Determine what constitutes Bath Salts, and their effects. 2) Learn how regulation is not inhibiting the production of 4) Determine what constitutes Synthetic Marijuana, and its designer drugs. effects BY ROMMIE L. DUCKWORTH emergency responders, and healthcare providers. Designer drugs are chemical compounds that are newly created, modi- April 5, 2011. Spanaway, Washington: Medic and Army Ser- fied, or repurposed to provide abusers with effects similar to geant Dave Stewart, high on bath salts bought at a local pipe currently illegal recreational drugs. They are often relatively shop, killed himself and his wife during a police pursuit. Their five-year-old son was also found dead in the car. easy to make and, because of their ever-changing ingredient list, are also extremely difficult to regulate. August 21, 2011. Bowling Green, Kentucky: Teenager Ashley The term “designer drugs” originated in the 1980s, but Stillwell became paralyzed while smoking 7H, a form of syn- the idea of marketing legal chemical combinations related thetic marijuana, with her friends. She lay on the floor, helpless, to regulated or banned drugs dates back to the 1920s. Such as her friends discussed what to do, including how to dispose of her body. -
N-Acyl-Dopamines: Novel Synthetic CB1 Cannabinoid-Receptor Ligands
Biochem. J. (2000) 351, 817–824 (Printed in Great Britain) 817 N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Tiziana BISOGNO*, Dominique MELCK*, Mikhail Yu. BOBROV†, Natalia M. GRETSKAYA†, Vladimir V. BEZUGLOV†, Luciano DE PETROCELLIS‡ and Vincenzo DI MARZO*1 *Istituto per la Chimica di Molecole di Interesse Biologico, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy, †Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, R. A. S., 16/10 Miklukho-Maklaya Str., 117871 Moscow GSP7, Russia, and ‡Istituto di Cibernetica, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy We reported previously that synthetic amides of polyunsaturated selectivity for the anandamide transporter over FAAH. AA-DA fatty acids with bioactive amines can result in substances that (0.1–10 µM) did not displace D1 and D2 dopamine-receptor interact with proteins of the endogenous cannabinoid system high-affinity ligands from rat brain membranes, thus suggesting (ECS). Here we synthesized a series of N-acyl-dopamines that this compound has little affinity for these receptors. AA-DA (NADAs) and studied their effects on the anandamide membrane was more potent and efficacious than anandamide as a CB" transporter, the anandamide amidohydrolase (fatty acid amide agonist, as assessed by measuring the stimulatory effect on intra- hydrolase, FAAH) and the two cannabinoid receptor subtypes, cellular Ca#+ mobilization in undifferentiated N18TG2 neuro- CB" and CB#. NADAs competitively inhibited FAAH from blastoma cells. This effect of AA-DA was counteracted by the l µ N18TG2 cells (IC&! 19–100 M), as well as the binding of the CB" antagonist SR141716A. -
The Selective Reversible FAAH Inhibitor, SSR411298, Restores The
www.nature.com/scientificreports OPEN The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive Received: 22 September 2017 Accepted: 26 January 2018 behaviors to acute and chronic Published: xx xx xxxx stress in rodents Guy Griebel1, Jeanne Stemmelin2, Mati Lopez-Grancha3, Valérie Fauchey3, Franck Slowinski4, Philippe Pichat5, Gihad Dargazanli4, Ahmed Abouabdellah4, Caroline Cohen6 & Olivier E. Bergis7 Enhancing endogenous cannabinoid (eCB) signaling has been considered as a potential strategy for the treatment of stress-related conditions. Fatty acid amide hydrolase (FAAH) represents the primary degradation enzyme of the eCB anandamide (AEA), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). This study describes a potent reversible FAAH inhibitor, SSR411298. The drug acts as a selective inhibitor of FAAH, which potently increases hippocampal levels of AEA, OEA and PEA in mice. Despite elevating eCB levels, SSR411298 did not mimic the interoceptive state or produce the behavioral side-efects (memory defcit and motor impairment) evoked by direct-acting cannabinoids. When SSR411298 was tested in models of anxiety, it only exerted clear anxiolytic-like efects under highly aversive conditions following exposure to a traumatic event, such as in the mouse defense test battery and social defeat procedure. Results from experiments in models of depression showed that SSR411298 produced robust antidepressant-like activity in the rat forced-swimming test and in the mouse chronic mild stress model, restoring notably the development of inadequate coping responses to chronic stress. This preclinical profle positions SSR411298 as a promising drug candidate to treat diseases such as post-traumatic stress disorder, which involves the development of maladaptive behaviors. Te endocannabinoid (eCB) system is formed by two G protein-coupled receptors, CB1 and CB2, and their main transmitters, N-arachidonoylethanolamine (anandamide; AEA) and 2-arachidonoyglycerol (2-AG)1. -
Nabilone for Chronic Pain Management: a Review of Clinical Effectiveness, Safety, and Guidelines
TITLE: Nabilone for Chronic Pain Management: A Review of Clinical Effectiveness, Safety, and Guidelines DATE: 11 November 2011 CONTEXT AND POLICY ISSUES Cannabis sativa is a flowering plant that has long been used as a recreational drug, and for medicinal purposes.1,2 The main psychoactive component of cannabis is delta-9- tetrahydrocannabinol (∆9-THC).2 Nabilone (Cesamet®) is an oral synthetic cannabinoid, which is licensed in Canada for treating patients with severe nausea and vomiting related to chemotherapy for cancer and who have failed to respond adequately to conventional antiemetic treatments.2-4 Clinical trials and anecdotal reports have suggested that the use of nabilone in other medical conditions, such as appetite stimulation, anxiety, spasticity, and pain.1,5 Chronic pain affects approximately one in five people in developed countries and two in five in less well-resourced countries. In many circumstances, the patient’s quality of life is poor due to persistent pain caused either by an ongoing illness or nerve damage caused by the disease after resolution or cure of the disease.6 Multiple sclerosis (MS) is a neurodegenerative disease, and is the most common cause of neurological disability in young people, with an average age of onset around 30 years and a prevalence of about 120 per 100,000 individuals in North America. The majority of patients with MS display symptoms, such as fatigue, muscle stiffness or spasticity, pain, memory problems, balance trouble, tremors, urinary disturbance, and sexual dysfunctions.2,7 The purpose of this review is to assess the evidence of benefits and harms related to the use of nabilone in management of chronic pain, including patients with MS. -
Trick Or Treat from Food Endocannabinoids?
scientific correspondence 3. Casselman, J. M. in Proc. 1980 North Am. Eel Conf. (ed. Loftus, NAEs (0.01–5.8 mg per g) and oleamide of magnitude below those required, if K. H.) 74–82 (Ontario Ministry of Natural Resources, Ontario, (0.17–6.0 g per g), but no or very little administered by mouth, to reach the blood 1982). m 4. Radtke, R. L. Comp. Biochem. Physiol. A 92, 189–193 (1989). anandamide and no 2-AG. NAE levels are and cause observable ‘central’ effects. The 5. Kalish, J. M. J. Exp. Mar. Biol. Ecol. 132, 151–178 (1989). much lower in unfermented cocoa beans assays used here provide a gross evaluation of 6. Secor, D. H. Fish. Bull. US 90, 798–806 (1992). than in cocoa powder (which contained less cannabimimetic activity, and tests 7. Tzeng, W. N., Severin, K. P. & Wickström, H. Mar. Ecol. Prog. Ser. 149, 73–81 (1997). than 0.003 mg per g anandamide). Tiny monitoring more subtle behavioural changes 8. Angino, E. E., Billings, G. K. & Anderson, N. Chem. Geol. 1, amounts of anandamide in cocoa could that might be induced by low oral doses of 145–153 (1966). therefore be explained as artefacts of pro- NAEs/oleamide are needed before the rele- 9. Nakai, I., Iwata, R. & Tsukamoto, K. Spectrochim. Acta B (in the 2 cessing . Like all higher plants, cocoa plants vance of these compounds to the purported press). 8 10. Otake, T., Ishii, T., Nakahara, M. & Nakamura, R. Mar. Ecol. cannot synthesize arachidonic acid or its mild rewarding and craving-inducing effects 7 Prog. -
Johnson, Current Trends in Workplace Drug Testing
LATEST TRENDS IN DRUG AND ALCOHOL TESTING Paul Johnson CEO Express Diagnostics Int’l Trends In Drug Use • Drive to get high! • People will seek any means to alter their state of consciousness Trends In Drug Use • Treatment admissions for opiates other than heroin rose from 19,870 in 1998 to 111,251 in 2008, over a 450-percent increase Trends In Drug Use 80% of the world's supply of opioid analgesics are consumed in the U.S, but we only have 5% of the world's population Trends In Drug Use California - Oxy abusers turning to heroin in San Diego County Designer Drugs • Created (or reformulated, if the drug already existed) to get around existing drug laws (Controlled Substance Act in the USA, TGA Poisons Act Aust.), usually by modifying the molecular structures of existing drugs to varying degrees. • What drives the production of designer drugs? . Consumer preferences . Law enforcement control Designer Drugs An agonist is a chemical that binds to a receptor and triggers a response – often mimicking the action of a naturally occurring substance. Receptor Drug (agonist) Designer Drugs • Why Change the Key? – Prolong the effect of the drug Drug – Increase the potency of the drug – “Select” the desired effect – Make the drug more difficult to detect – Avoid patent infringement – Make an illegal drug “legal Spice/K2 • No! We are not talking about this! Spice/K2 / Kronic • We are talking about this! Spice/K2 – Usage • Commonly used in the mining industry as many mines still don’t test for it yet, despite the fact that accurate, reliable tests do exist now. -
Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions. -
Medicinal Chemistry Endeavors Around the Phytocannabinoids
CHEMISTRY & BIODIVERSITY – Vol. 4 (2007) 1707 REVIEW Medicinal Chemistry Endeavors around the Phytocannabinoids by Eric Stern and Didier M. Lambert* Drug Design and Discovery Center and Unite´ de Chimie pharmaceutique et de Radiopharmacie, Ecole de Pharmacie, Faculte´ de Me´decine, Universite´ catholique de Louvain, Avenue E. Mounier 73, U.C.L. 73.40, B-1200 Bruxelles (phone: þ3227647347; fax: þ3227647363; e-mail: [email protected]) Over the past 50 years, a considerable research in medicinal chemistry has been carried out around the natural constituents of Cannabis sativa L. Following the identification of D9-tetrahydrocannabinol (D9-THC) in 1964, critical chemical modifications, e.g., variation of the side chain at C(3) and the opening of the tricyclic scaffold, have led to the characterization of potent and cannabinoid receptor subtype-selective ligands. Those ligands that demonstrate high affinity for the cannabinoid receptors and good biological efficacy are still used as powerful pharmacological tools. This review summarizes past as well as recent developments in the structure–activity relationships of phytocannabinoids. 1. Introduction. – Despite the wide uses of preparations of the hemp Cannabis sativa L. during the History, the modern pharmacology of natural cannabinoids has been hampered by the slow progress in the elucidations of the chemical structures of its major components. Indeed, it is nowadays known that more than 70 compounds derived from a diterpene structure are present in the plant [1], and this fact may explain the difficulty to obtain pure chemical entities in the past. In addition, the medicinal research for more than a half century has been driven by the search for the components responsible for the psychoactive effects of cannabis, this era in the history of the chemical research on cannabinoids have been recently reviewed [2][3]. -
Redalyc.Leguminosae
Biota Neotropica ISSN: 1676-0611 [email protected] Instituto Virtual da Biodiversidade Brasil Caboco, Rafael Brune; Prates Rolim, Thiago; Bagnatori Sartori, Ângela Lúcia; Sciamarelli, Alan Leguminosae-papilionoideae from the parque estadual das Várzeas do Rio Ivinhema, Mato Grosso do Sul State, Brazil Biota Neotropica, vol. 12, núm. 2, 2012, pp. 57-70 Instituto Virtual da Biodiversidade Campinas, Brasil Available in: http://www.redalyc.org/articulo.oa?id=199123113007 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Leguminosae-papilionoideae from the parque estadual das Várzeas do Rio Ivinhema, Mato Grosso do Sul State, Brazil Caboco, R.B. et al. Biota Neotrop. 2012, 12(2): 57-70. On line version of this paper is available from: http://www.biotaneotropica.org.br/v12n1/en/abstract?article+bn01212022012 A versão on-line completa deste artigo está disponível em: http://www.biotaneotropica.org.br/v12n2/pt/abstract?article+bn01212022012 Received/ Recebido em 05/09/11 - Revised/ Versão reformulada recebida em 24/04/12 - Accepted/ Publicado em 24/02/12 ISSN 1676-0603 (on-line) Biota Neotropica is an electronic, peer-reviewed journal edited by the Program BIOTA/FAPESP: The Virtual Institute of Biodiversity. This journal’s aim is to disseminate the results of original research work, associated or not to the program, concerned with characterization, conservation and sustainable use of biodiversity within the Neotropical region. Biota Neotropica é uma revista do Programa BIOTA/FAPESP - O Instituto Virtual da Biodiversidade, que publica resultados de pesquisa original, vinculada ou não ao programa, que abordem a temática caracterização, conservação e uso sustentável da biodiversidade na região Neotropical. -
Federal Register/Vol. 84, No. 214/Tuesday, November 5, 2019
Federal Register / Vol. 84, No. 214 / Tuesday, November 5, 2019 / Notices 59645 Authority: 42 U.S.C. 6213; and 30 CFR company plans to bulk manufacture Controlled substance Drug Schedule 556.511–556.515. these drugs as synthetics. No other code Walter D. Cruickshank, activities for these drug codes are Hydromorphone ....................... 9150 II Acting Director, Bureau of Ocean Energy authorized for this registration. Hydrocodone ............................ 9193 II Management. Morphine .................................. 9300 II Dated: October 18, 2019. Oripavine .................................. 9330 II [FR Doc. 2019–24052 Filed 11–4–19; 8:45 am] William T. McDermott, Thebaine .................................. 9333 II BILLING CODE 4310–MR–P Assistant Administrator. Opium extracts ......................... 9610 II Opium fluid extract ................... 9620 II [FR Doc. 2019–24107 Filed 11–4–19; 8:45 am] Opium tincture ......................... 9630 II BILLING CODE 4410–09–P Opium, powdered .................... 9639 II DEPARTMENT OF JUSTICE Opium, granulated ................... 9640 II Oxymorphone .......................... 9652 II Drug Enforcement Administration Noroxymorphone ..................... 9668 II DEPARTMENT OF JUSTICE Tapentadol ............................... 9780 II [Docket No. DEA–536] Drug Enforcement Administration The company plans to manufacture Bulk Manufacturer of Controlled [Docket No. DEA–526] the listed controlled substances as an Substances Application: Organix, Inc. Active Pharmaceutical Ingredient (API) Bulk -
2 Spice English Presentation
Spice Spice contains no compensatory substances Специи не содержит компенсационные вещества Spice is a mix of herbs (shredded plant material) and manmade chemicals with mind-altering effects. It is often called “synthetic marijuana” because some of the chemicals in it are similar to ones in marijuana; but its effects are sometimes very different from marijuana, and frequently much stronger. It is most often labeled “Not for Human Consumption” and disguised as incense. Eliminationprocess • The synthetic agonists such as THC is fat soluble. • Probably, they are stored as THC in cell membranes. • Some of the chemicals in Spice, however, attach to those receptors more strongly than THC, which could lead to a much stronger and more unpredictable effect. • Additionally, there are many chemicals that remain unidentified in products sold as Spice and it is therefore not clear how they may affect the user. • Moreover, these chemicals are often being changed as the makers of Spice alter them to avoid the products being illegal. • To dissolve the Spice crystals Acetone is used endocannabinoids synhtetic THC cannabinoids CB1 and CB2 agonister Binds to cannabinoidreceptor CB1 CB2 - In the brain -in the immune system Decreased avtivity in the cell ____________________ Maria Ellgren Since some of the compounds have a longer toxic effects compared to naturally THC, as reported: • negative effects that often occur the day after consumption, as a general hangover , but without nausea, mentally slow, confused, distracted, impairment of long and short term memory • Other reports mention the qualitative impairment of cognitive processes and emotional functioning, like all the oxygen leaves the brain. -
Introduced B.,Byhansen, 16
LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.